Neuropathy News and Research

RSS

NeuroMetrix second quarter total revenues decrease to $2.6 million

NeuroMetrix, Inc., a science-based health care company improving patient care through neurotechnology, today reported business and financial highlights for the quarter and six months ended June 30, 2011.

28 Jul 2011

Des Moines hospital faces review; $9 million hospital bill in Tampa

In state hospital news, federal regulators have ordered Iowa officials to study the Mercy Medical Center, and Florida officials say a Tampa hospital has filed a $9.2 million claim against the estate of a former patient. In other news, officials begin the process of closing Walter Reed Army Medical Center.

28 Jul 2011

Advancements in use of zinc finger nucleases to produce genetically modified pigs

Sangamo BioSciences, Inc. announced the publication of a study demonstrating the use of zinc finger nucleases (ZFNs) to produce genetically modified pigs. The study, which was published in the Proceedings of the National Academy of Sciences (PNAS), represents a significant advancement in the development of improved, less immunogenic animal tissue as a source for transplant into humans.

22 Jul 2011

Baxter net income increases 15% to $615 million for second quarter 2011

Baxter International Inc. today announced strong financial results for the second quarter of 2011, and raised its financial outlook for full-year 2011.

From Baxter International Inc. 21 Jul 2011

Essential criteria for clinical diagnosis of restless legs syndrome

We've all experienced abnormal sensations in our legs at one time or another, but for as many as 10 percent of the US population, restless legs syndrome (RLS) is a daily occurrence. Characterized by throbbing, pulling, tingling, itching, and crawling sensations, RLS is a neurological disorder that produces unpleasant physical sensations in the extremities and an urge to counteract that sensation by movement.

21 Jul 2011

Millennium submits VELCADE sNDA to FDA to add OS data for previously untreated multiple myeloma

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced the submission of a supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration for VELCADE® (bortezomib) for injection to add overall survival data after a five-year follow up to the product label.

20 Jul 2011

EC approves YERVOY for treatment of previously-treated advanced melanoma

Bristol-Myers Squibb today announced that the European Commission has approved YERVOY for the treatment of adult patients with previously-treated advanced melanoma.

14 Jul 2011

STSI receives NIH grant to conduct heart-based research

Researchers looking to find a root cause for heart attacks and coronary artery disease will soon begin using a novel investigative approach that borders on science fiction as they work toward the holy grail of American medicine: preventing the nation's No. 1 killer.

2 Jul 2011

Expert addresses need to improve risk stratification of heart failure patients eligible for ICD or CRT-D

Responding to a recent study showing that 40% of patients who receive CRT-ICD therapy do not benefit from the device (Sipahi, et al – 6/13/11), Wojciech Zareba, MD, PhD, stated that improving risk stratification of heart failure patients eligible for an implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy with a defibrillator (CRT-D) is essential.

28 Jun 2011

EMA CHMP issues positive opinion for Baxter's IVIG therapy for multifocal motor neuropathy

Baxter International Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for extension of the therapeutic indications of KIOVIG to include a new indication for multifocal motor neuropathy (MMN), a severe, debilitating disorder requiring lifelong treatment.

From Baxter International Inc. 24 Jun 2011

Diabetic neuropathy patients with wounds must protect themselves from pets

In a case study that illustrates the need for people with diabetes to be cautious of foot injuries and to protect themselves from pets, a woman with numbness in her feet caused by diabetic neuropathy slept through a traumatic episode in which her Jack Russell terrier chewed off part of her slightly infected big toe, according to an article published in this month's issue of the Journal of the American Podiatric Medical Association.

24 Jun 2011

InVasc commences INV-144 Phase IIa trial in chronic kidney disease

InVasc Therapeutics, Inc., announced today that it has initiated a Phase IIa, proof of concept (POC), clinical trial with INV-144, a combination drug of losartan with alpha Lipoic Acid (ALA), to slow the progression of chronic kidney disease (CKD) in hypertensive diabetic patients.

24 Jun 2011

New strategy to prevent amputations

Blood vessels and supporting cells appear to be pivotal partners in repairing nerves ravaged by diabetic neuropathy, and nurturing their partnership with nerve cells might make the difference between success and failure in experimental efforts to regrow damaged nerves, Johns Hopkins researchers report in a new study.

24 Jun 2011

Health Canada grants market authorization for Sanofi-aventis Jevtana to treat prostate cancer

Sanofi-aventis announced today that Health Canada has granted market authorization for Jevtana injection in combination with prednisone for the treatment of patients with metastatic castration resistant prostate cancer, previously treated with a docetaxel-containing treatment regimen.

24 Jun 2011

NeuroMetrix to introduce NC-stat DPNCheck device for diabetic peripheral neuropathy

NeuroMetrix, Inc. announced today that it expects to meet its planned launch date for its latest product, NC-stat|DPNCheck, which is a fast, accurate, and quantitative test for the evaluation of systemic neuropathies such as diabetic peripheral neuropathy.

21 Jun 2011

Benitec’s pain program validated by independent study

Benitec Ltd (ASX:BLT), a world leader in RNA-based gene silencing for human therapeutics, announced that China-based researchers have proved the concept behind Benitec's in house neuropathic pain program.

20 Jun 2011

REVLIMID-R-CHOP Phase I/II data in untreated DLBCL presented at malignant lymphoma conference

Celgene International Sàrl announced that clinical data from two studies evaluating the use of REVLIMID® (lenalidomide) with standard R-CHOP chemotherapy in patients with untreated diffuse large B cell (DLBCL) or grade 3 follicular lymphoma were presented at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland.

17 Jun 2011

Hopkins research suggests that blood vessels and support cells may be real targets of treatment for diabetic nerve damage

16 Jun 2011

Enrollment complete in NeurogesX NGX-1998 Phase 2 clinical study for postherpetic neuralgia

NeurogesX, Inc., a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced the completion of patient enrollment in its Phase 2 clinical study of NGX-1998, a topical liquid formulation of high-concentration capsaicin, in patients with postherpetic neuralgia (PHN).

16 Jun 2011

Millennium reports results from two MLN9708 ongoing Phase I studies on multiple myeloma

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today reported results from two ongoing Phase I studies with MLN9708, the first oral proteasome inhibitor being studied in patients with relapsed and/or refractory multiple myeloma.

13 Jun 2011

Neuropathy News and Research

NeuroMetrix second quarter total revenues decrease to $2.6 million

Des Moines hospital faces review; $9 million hospital bill in Tampa

Advancements in use of zinc finger nucleases to produce genetically modified pigs

Baxter net income increases 15% to $615 million for second quarter 2011

Essential criteria for clinical diagnosis of restless legs syndrome

Millennium submits VELCADE sNDA to FDA to add OS data for previously untreated multiple myeloma

EC approves YERVOY for treatment of previously-treated advanced melanoma

STSI receives NIH grant to conduct heart-based research

Expert addresses need to improve risk stratification of heart failure patients eligible for ICD or CRT-D

EMA CHMP issues positive opinion for Baxter's IVIG therapy for multifocal motor neuropathy

Diabetic neuropathy patients with wounds must protect themselves from pets

InVasc commences INV-144 Phase IIa trial in chronic kidney disease

New strategy to prevent amputations

Health Canada grants market authorization for Sanofi-aventis Jevtana to treat prostate cancer

NeuroMetrix to introduce NC-stat DPNCheck device for diabetic peripheral neuropathy

Benitec’s pain program validated by independent study

REVLIMID-R-CHOP Phase I/II data in untreated DLBCL presented at malignant lymphoma conference

Hopkins research suggests that blood vessels and support cells may be real targets of treatment for diabetic nerve damage

Enrollment complete in NeurogesX NGX-1998 Phase 2 clinical study for postherpetic neuralgia

Millennium reports results from two MLN9708 ongoing Phase I studies on multiple myeloma

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News